Inspection Record

Beauty Mark Solutions Inc — Health Canada Inspection Findings

Health CanadaInspected 2023-07-25 16 findingsLabeling and packagingEquipment and facilityLaboratory and QC controlsOther quality systemDeviation, CAPA, and investigationStability and storageRegulatory reporting and change controlQuality unit oversightMaterial and supplier control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Labeling and packaging

The quality agreement outlining the responsibilities for fabricating, packaging or labelling, and/or testing was inadequate.

2Equipment and facility

The training of personnel in good manufacturing practices and/or the maintenance of records was inadequate.

3Laboratory and QC controls

The validation of test methods was inadequate.

4Equipment and facility

Evaluation of production processes, equipment, and/or materials was inadequate. The master production documents were inadequate.

5Other quality system

The implementation of a self-inspection program was inadequate.

6Labeling and packaging

The importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).

7Deviation, CAPA, and investigation

Investigations into deviations, reports, and/or follow-up actions were inadequate.

8Stability and storage

The ongoing stability program for a drug was inadequate.

9Other quality system

The assessment to release finished products was inadequate.

10Regulatory reporting and change control

The change control system was inadequate for ensuring changes are properly documented, evaluated, and/or approved.

11Quality unit oversight

The annual product quality review procedure was inadequate. The quality control department did not evaluate the results of the annual product quality review.

12Other quality system

The assessment, documentation, and/or procedures for considering the resale of returned drugs were inadequate.

13Material and supplier control

The company did not determine the stability of the drug before it was marketed or before significant changes were made to the drug formulations, fabrication procedures, or packaging materials.

14Equipment and facility

The maintenance of records was inadequate.

15Other quality system

The written specifications were inadequate.

16Laboratory and QC controls

Senior management's ability to determine and/or provide adequate and/or appropriate resources to implement, maintain and/or improve the effectiveness of the quality management system was inadequate. The quality control department did not undertake all of the required activities.

About this record

Extracted automatically from the document of the Health Canada inspection on 2023-07-25. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Beauty Mark Solutions Inc findings history — including this company's other documents Health Canada documents, 2023 Go to Findings search